ONCOSEC MEDICAL INCORPORATED Research and Development Expense
ONCOSEC MEDICAL INCORPORATED reported Research and Development Expense of $4.65 million for the 3-month period ending 2023-01-31, per its 10-Q filed 2023-03-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-03-14
- ONCOSEC MEDICAL INCORPORATED research and development expense for the quarter ending 2023-01-31 was $4.65M, a 31.82% decline year-over-year.
- ONCOSEC MEDICAL INCORPORATED research and development expense for the quarter ending 2022-10-31 was $4.77M, a 28.25% decline year-over-year.
- ONCOSEC MEDICAL INCORPORATED research and development expense for the quarter ending 2022-07-31 was $5.32M, a 31.74% decline year-over-year.
- ONCOSEC MEDICAL INCORPORATED research and development expense for the quarter ending 2022-04-30 was $7.03M, a 7.37% decline year-over-year.
- ONCOSEC MEDICAL INCORPORATED research and development expense for fiscal 2022 was $25.82M, a 24.27% decline from fiscal 2021.
- ONCOSEC MEDICAL INCORPORATED research and development expense for fiscal 2021 was $34.10M, a 35.86% increase from fiscal 2020.
- ONCOSEC MEDICAL INCORPORATED research and development expense for fiscal 2020 was $25.10M, a 36.06% increase from fiscal 2019.
- ONCOSEC MEDICAL INCORPORATED research and development expense for fiscal 2019 was $18.45M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2023-01-31 | $4.65M 10-Q · filed 2023-03-14 | $9.42M 10-Q · filed 2023-03-14 | $14.74M derived: sum of 3 quarters · filed 2023-03-14 | $21.77M derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-10-31 | $4.77M 10-Q · filed 2022-12-15 | $10.09M derived: sum of 2 quarters · filed 2022-12-15 | $17.12M derived: sum of 3 quarters · filed 2022-12-15 | $23.94M derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-07-31 | $5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $12.35M derived: sum of 2 quarters · filed 2022-10-31 | $19.18M derived: sum of 3 quarters · filed 2023-03-14 | $25.82M 10-K · filed 2022-10-31 |
| 2022-04-30 | $7.03M 10-Q · filed 2022-06-14 | $13.86M derived: sum of 2 quarters · filed 2023-03-14 | $20.50M 10-Q · filed 2022-06-14 | $28.30M derived: sum of 4 quarters · filed 2023-03-14 |
| 2022-01-31 | $6.83M 10-Q · filed 2023-03-14 | $13.47M 10-Q · filed 2023-03-14 | $21.26M derived: sum of 3 quarters · filed 2023-03-14 | $28.85M derived: sum of 4 quarters · filed 2023-03-14 |
| 2021-10-31 | $6.65M 10-Q · filed 2022-12-15 | $14.44M derived: sum of 2 quarters · filed 2022-12-15 | $22.03M derived: sum of 3 quarters · filed 2022-12-15 | $30.94M derived: sum of 4 quarters · filed 2022-12-15 |
| 2021-07-31 | $7.79M derived: 10-K 12 month − 10-Q 9 month · filed 2022-10-31 | $15.38M derived: sum of 2 quarters · filed 2022-10-31 | $24.30M derived: sum of 3 quarters · filed 2022-10-31 | $34.10M 10-K · filed 2022-10-31 |
| 2021-04-30 | $7.59M 10-Q · filed 2022-06-14 | $16.51M derived: sum of 2 quarters · filed 2022-06-14 | $26.30M 10-Q · filed 2022-06-14 | $33.82M derived: sum of 4 quarters · filed 2022-06-14 |
| 2021-01-31 | $8.92M 10-Q · filed 2022-03-15 | $18.71M 10-Q · filed 2022-03-15 | $26.23M derived: sum of 3 quarters · filed 2022-03-15 | $32.33M derived: sum of 4 quarters · filed 2022-03-15 |
| 2020-10-31 | $9.80M 10-Q · filed 2021-12-15 | $17.31M derived: sum of 2 quarters · filed 2021-12-15 | $23.41M derived: sum of 3 quarters · filed 2021-12-15 | $29.47M derived: sum of 4 quarters · filed 2021-12-15 |
| 2020-07-31 | $7.51M derived: 10-K 12 month − 10-Q 9 month · filed 2021-10-29 | $13.61M derived: sum of 2 quarters · filed 2021-10-29 | $19.67M derived: sum of 3 quarters · filed 2021-10-29 | $25.10M 10-K · filed 2021-10-29 |
| 2020-04-30 | $6.10M 10-Q · filed 2021-06-11 | $12.16M derived: sum of 2 quarters · filed 2021-06-11 | $17.59M 10-Q · filed 2021-06-11 | $22.32M derived: sum of 4 quarters · filed 2021-06-11 |
| 2020-01-31 | $6.06M 10-Q · filed 2021-03-15 | $11.49M 10-Q · filed 2021-03-15 | $16.21M derived: sum of 3 quarters · filed 2021-03-15 | $20.43M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-10-31 | $5.42M 10-Q · filed 2020-12-11 | $10.16M derived: sum of 2 quarters · filed 2020-12-11 | $14.38M derived: sum of 3 quarters · filed 2020-12-11 | $19.13M derived: sum of 4 quarters · filed 2020-12-11 |
| 2019-07-31 | $4.74M derived: 10-K 12 month − 10-Q 9 month · filed 2020-10-28 | $8.96M derived: sum of 2 quarters · filed 2020-10-28 | $13.71M derived: sum of 3 quarters · filed 2020-10-28 | $18.45M 10-K · filed 2020-10-28 |
| 2019-04-30 | $4.22M 10-Q · filed 2020-06-15 | $8.97M derived: sum of 2 quarters · filed 2020-06-15 | $13.71M 10-Q · filed 2020-06-15 | |
| 2019-01-31 | $4.75M 10-Q · filed 2020-03-16 | $9.49M 10-Q · filed 2020-03-16 | ||
| 2018-10-31 | $4.74M 10-Q · filed 2019-12-13 | |||
| 2017-07-31 | $3.31M 10-K · filed 2017-10-25 | $5.97M derived: sum of 2 quarters · filed 2017-10-25 | $8.85M derived: sum of 3 quarters · filed 2017-10-25 | $11.95M derived: sum of 4 quarters · filed 2017-10-25 |
| 2017-04-30 | $2.66M 10-K · filed 2017-10-25 | $5.54M derived: sum of 2 quarters · filed 2017-10-25 | $8.64M derived: sum of 3 quarters · filed 2017-10-25 | $12.23M derived: sum of 4 quarters · filed 2017-10-25 |
| 2017-01-31 | $2.88M 10-K · filed 2017-10-25 | $5.98M derived: sum of 2 quarters · filed 2017-10-25 | $9.57M derived: sum of 3 quarters · filed 2017-10-25 | $12.95M derived: sum of 4 quarters · filed 2017-10-25 |
| 2016-10-31 | $3.10M 10-K · filed 2017-10-25 | $6.69M derived: sum of 2 quarters · filed 2017-10-25 | $10.07M derived: sum of 3 quarters · filed 2017-10-25 | $14.18M derived: sum of 4 quarters · filed 2017-10-25 |
| 2016-07-31 | $3.59M 10-K · filed 2017-10-25 | $6.97M derived: sum of 2 quarters · filed 2017-10-25 | $11.08M derived: sum of 3 quarters · filed 2017-10-25 | $14.74M derived: sum of 4 quarters · filed 2017-10-25 |
| 2016-04-30 | $3.38M 10-K · filed 2017-10-25 | $7.49M derived: sum of 2 quarters · filed 2017-10-25 | $11.15M derived: sum of 3 quarters · filed 2017-10-25 | |
| 2016-01-31 | $4.11M 10-K · filed 2017-10-25 | $7.77M derived: sum of 2 quarters · filed 2017-10-25 | ||
| 2015-10-31 | $3.66M 10-K · filed 2017-10-25 |